CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

NCT00574730 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG: CHOP/Rituximab
DRUG: PEG INTRON

Sponsor

University of Nebraska

Collaborators

[object Object]